कंपनी का अवलोकन
eXoZymes, Inc. operates as a development stage biotechnology enterprise dedicated to the creation of enzyme modules and cell-free exozyme biosolutions designed specifically for synthetic biology manufacturing applications. The entity functions within the Healthcare sector and the Biotechnology industry, positioning itself in a high-growth, research-intensive segment that relies heavily on intellectual property and technological innovation rather than immediate commercial scale. The company currently maintains a market capitalization of $96.66M and employs a workforce of 32 individuals to support its developmental activities. The absence of reported annual revenue in the available data suggests that the organization remains in an early-stage phase where capital is predominantly allocated toward research and development rather than large-scale commercial sales operations. This market capitalization relative to the lack of revenue indicates a valuation primarily based on potential future assets and technological capabilities rather than current cash flow generation, which is typical for biotechnology firms in their formative years. The transition from its former identity as Invizyne Technologies, Inc. to eXoZymes, Inc. reflects a strategic rebranding that underscores its focus on exozyme-based technologies within the broader synthetic biology landscape.
वित्तीय स्वास्थ्य
The financial statements for the trailing twelve months report a net income of $-9,158,734 and an EBITDA of $-9,428,510, while revenue figures are not available in the provided data. The substantial gap between the reported net income and the negative EBITDA reveals a cost structure where interest expenses or other non-operating charges significantly impact the bottom line, though the specific magnitude of these charges cannot be isolated without revenue data. Free cash flow stands at $-3,628,369, indicating that the company is burning cash at a significant rate to fund its operations and development pipeline. This negative free cash flow implies limited financial flexibility, requiring the entity to rely on external financing, equity issuance, or existing cash reserves to sustain its activities. All three margin metrics—gross margin, operating margin, and profit margin—are reported as 0.0%, which indicates that the company has not yet achieved commercial profitability or that its financial reporting does not reflect traditional margin expansion due to the development stage nature of the business. The company holds $3.04M in cash against $1.24M in debt, resulting in a debt-to-equity ratio of 36.59, which suggests a leveraged balance sheet relative to equity but manageable given the current asset base. The current ratio of 2.51 indicates that the company possesses sufficient liquid assets to cover its short-term liabilities more than twice over, pointing to a relatively strong short-term liquidity position despite the overall cash burn. Return on Equity is -132.6% and Return on Assets is -63.9%, metrics that reveal that management has not yet generated positive returns on the capital invested by shareholders or accumulated in assets, a common characteristic of early-stage biotechnology companies that are prioritizing growth and product development over immediate profitability.
मूल्यांकन आकलन
The trailing P/E ratio and forward P/E ratio are both listed as N/A, as the company has not reported positive earnings required to calculate these standard multiples. The absence of a positive P/E implies that traditional earnings-based valuation models are not applicable, and investors must rely on alternative metrics to assess the company's worth. The price-to-book ratio is 28.22, indicating that the market values the company at a significant premium over its net book value, likely driven by the intangible value of its proprietary enzyme technologies and future development potential. The price-to-sales ratio is N/A due to the lack of reported revenue, while the EV/EBITDA stands at -10.06, which further highlights the company's negative earnings position and the challenges in applying standard enterprise value multiples to a loss-making development stage entity. The stock has traded between a 52-week low of $7.08 and a 52-week high of $18.40, and without a specific current price to calculate the exact percentage deviation, the trading range demonstrates a volatility of over 150% over the past year. The beta value is N/A, meaning that standard measures of price volatility relative to the broader market are not available for this specific ticker. These valuation metrics collectively suggest that the stock is priced based on speculative growth expectations and technological potential rather than current financial fundamentals or historical earnings performance.
Growth & Income
Revenue growth and earnings growth rates are both N/A, as the company has not generated sufficient revenue to calculate year-over-year growth percentages in the available data. The inability to determine growth rates implies that the business is still in a phase where absolute revenue figures are either minimal or not yet standardized for comparative analysis. Since the company does not pay dividends, there is no dividend yield or payout ratio to evaluate for sustainability, as the payout ratio is 0.0%. This absence of dividend distribution indicates that the company retains all of its earnings, however minimal, to reinvest directly into research, development, and the expansion of its synthetic biology manufacturing capabilities. The overall growth and income profile of eXoZymes, Inc. is characterized by a total reliance on capital appreciation potential rather than income generation or revenue expansion at this stage of its lifecycle.